MedTrace Logo

Accelerated iTBS for PTSD and Depression

NCT07682207 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-07-02

No results posted yet for this study

Summary

The goal of this pilot clinical trial is to learn if a faster brain stimulation schedule is practical, safe, tolerable, and acceptable. This study looks at accelerated intermittent theta burst stimulation, or accelerated iTBS. This is a non-invasive type of magnetic brain stimulation. This study is for adults with post-traumatic stress disorder (PTSD) and major depressive disorder (MDD).

The main questions this study aims to answer are:

1. Can participants complete six short brain stimulation sessions per day for five days?
2. Is this treatment schedule safe and tolerable for participants?
3. What changes occur in depression symptoms, PTSD symptoms, anxiety, quality of life, and brain activity over time?

Participants will:

1. Complete health screening and baseline assessments.
2. Receive six short sessions of magnetic brain stimulation per day for five days.
3. Have their brain activity measured using an EEG recording.
4. Return for a post-treatment assessment at Week 2 and follow-up visits at Week 5 and Week 12.

Conditions

  • Post Traumatic Stress Disorder PTSD
  • Major Depressive Disorder (MDD)

Interventions

DEVICE

Accelerated intermittent theta burst stimulation

Accelerated intermittent theta burst stimulation, also called accelerated iTBS, is a non-invasive magnetic brain stimulation intervention. Stimulation is delivered to the left dorsolateral prefrontal cortex using a transcranial magnetic stimulation system. Participants receive six short sessions per day over five consecutive days.

Sponsors & Collaborators

  • Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Radhika Kelkar, MD · St. Joseph's Health Care London, Parkwood Institute, Finch Family Mental Health Care Building

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2027-06-30
Completion
2027-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07682207 on ClinicalTrials.gov